Diagnostics specialist Hologic Inc. is slated to become the newest player in the aesthetics market with its proposed acquisition of Westford, Mass.-based Cynosure Inc. for $1.65 billion. Shares of Cynosure (NASDAQ:CYNO) jumped about 28 percent in trading to $65.95, on Tuesday. Bedford, Mass.-based Hologic executives said the all-cash deal could close in either late March or April.
Botox specialist Allergan plc is acquiring body-contouring product maker Zeltiq Aesthetics Inc. in a deal for about $2.48 billion. Shares of Pleasanton, Calif.-based Zeltiq Aesthetics Inc. (NASDAQ:ZLTQ) were at an all-time high, up 13.2 percent closing at $55.93 on Monday. Zeltiq has developed the Coolsculpting system, an FDA-approved technology that uses a cooling mechanism to reduce the appearance of stubborn fat. Dublin-based Allergan, which has been on a buying spree since its failed merger with Pfizer Inc. last April, said it would close the Zeltiq acquisition in 2Q17. For the past few years Zeltiq has...
Botox specialist Allergan plc is acquiring body-contouring product maker Zeltiq Aesthetics Inc. in a deal for about $2.48 billion. Shares of Pleasanton, Calif.-based Zeltiq Aesthetics Inc. (NASDAQ:ZLTQ) were at an all-time high, up 13.2 percent closing at $55.93 on Monday. Zeltiq has developed the Coolsculpting system, an FDA-approved technology that uses a cooling mechanism to reduce the appearance of stubborn fat.
Med-tech startup Flow Forward LLC said it has raised a total of $7 million in its series A round. The news comes around the same time the private company reported completing two studies evaluating its Arteriovenous Fistula Eligibility (AFE) system for use in hemodialysis patients. The Olathe, Kan.-based company's device is a small, minimally invasive blood pump system designed for temporary use to rapidly dilate peripheral veins through flow-mediated vascular dilation prior to arteriovenous fistula (AVF). The AVF procedure establishes a direct...
Med-tech startup Flow Forward LLC said it has raised a total of $7 million in its series A round. The news comes around the same time the private company reported completing two studies evaluating its Arteriovenous Fistula Eligibility (AFE) system for use in hemodialysis patients.
Health care data analytics start-up Intensix Ltd. brought in $8.3 million in its series A funding round. The Netanya, Israel-based company has developed a real-time predictive analytics platform for the early detection of patient deterioration in the intensive care unit (ICU) and high acuity departments of hospitals. Pitango Venture Capital led the round.
Cardiovascular genomic's specialist Cardiodx Inc.'s test to detect obstructive coronary artery disease (CAD) received long-term validation from a study published in this month's American Heart Journal. The Corus CAD test was evaluated in a genomic sub study of the Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE), which was sponsored by the National Heart, Lung and Blood Institute. PROMISE results come shortly after the Redwood City, Calif.-based company raised $18.1 million in equity financing from a total offering amount of $41.8 million, last month. The 2,370-patient study showed that individuals with low Corus...
Cardiovascular genomic's specialist Cardiodx Inc.'s test to detect obstructive coronary artery disease (CAD) received long-term validation from a study published in this month's American Heart Journal. The Corus CAD test was evaluated in a genomic sub study of the Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE), which was sponsored by the National Heart, Lung and Blood Institute.
